Comparison of the prognostic performance between OncoMasTR and OncotypeDX multigene signatures in hormone receptor-positive, HER2-negative, lymph node-negative breast cancer

Authors :: Seodhna M. Lynch
Verena Amberger-Murphy
Joanna Fay
Katherine M. Sheehan
Niamh Russell
Anthony O'Grady
Stephen Barron
Darran P. O'Connor
Catherine M. Kelly
Bozena Fender
John Crown
Anurati Saha
Chan-Ju Angel Wang
Tony Loughman
Desmond O'Leary
Peter Dynoodt
Cesar Lopez Ruiz
William M. Gallagher
Source :: Journal of Clinical Oncology. 36:12074-12074
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: 12074Background: Multigene prognostic signatures (MGPS) enable identification of early stage breast cancer (BC) patients requiring less aggressive treatment. OncoMasTR is a new MGPS found via a nov...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
HER2 negative
Lymph node negative
medicine.disease
Breast cancer
Hormone receptor
Internal medicine
medicine
Stage (cooking)
business

Full Text Access

Tools